Understanding Carfilzomib Dosing for Multiple Myeloma

Watch below our interview with Dr. Sharlene Dong from UT Southwestern Medical Center, who shared with us the results from her poster presentation at EHA 2024: 'Real-World Carfilzomib Prescribing Patterns And Outcomes For Patients With Relapsed Refractory Multiple Myeloma'.

This study aimed to understand the most common dosing schedules of carfilzomib (Kyprolis, Amgen) being administered in the US in both academic and community cancer centers, why they change from patient to patient, and determine the most effective one for patients with myeloma that has come back after treatment or stopped responding to treatment (relapsed/refractory). 

What Did They Find Out About Carfilzomib Dosing?

• Once-a-week carfilzomib is becoming more common: When carfilzomib was first used, patients usually received it twice a week. Now, giving it once a week (both 56mg/m² and 70mg/m²) is becoming the preferred way to give the treatment.
• The research shows similar benefits: Dr. Dong's study found that patients have similar outcomes whether they get carfilzomib once a week or twice a week, regardless of the dose. This is important because once-weekly dosing may be more convenient for patients.

What Factors Affect Carfilzomib Dosing?

The research also looked at what influences the decision about how often to give carfilzomib. These factors include:

• Where you're being treated: Treatment patterns can differ between large hospitals and local cancer centers.
• Your insurance plan: Insurance coverage can sometimes affect treatment choices.
• Your overall health: Your doctor considers your overall health and other medical conditions when deciding on the best treatment plan.
• Other medications you're taking: Carfilzomib is often given with other myeloma drugs in doublet or triplet regimens, and these combinations can influence dosing.

Real-World Research Matters

Studies like Dr. Dong's are crucial because they look at how treatments really work in the lives of patients. This helps doctors understand which treatments are not only effective but also fit best with patients' daily routines and preferences. If you have questions about carfilzomib or your treatment plan, talk to your doctor. They can help you understand your options and make the best choices for your individual needs.

At HealthTree, we believe patients are essential research partners. Sharing your experiences through HealthTree Cure Hub can help advance our understanding of multiple myeloma and improve care for everyone affected by this disease.

Learn more about our research and how you can get involved:

HealthTree Active Research Projects

Sources: 

• Real-World Carfilzomib Prescribing Patterns And Outcomes For Patients With Relapsed Refractory Multiple Myeloma